Capital Bluecross gene expression CUP Coverage Update

Coverage Criteria and Rationale

Investigational / Not covered as medically necessary

Covered when ALL of the following are met

Investigational stance: Gene expression and/or comprehensive genomic profiling to evaluate the site of origin of a tumor of unknown primary, to distinguish a primary from a metastatic tumor, or to guide treatment selection is considered investigational

Insufficient evidence to support clinical benefit; not covered as medically necessary

Medical necessity and evidence conclusion

Summary of evidence and coverage stance

Evidence summary: Clinical validity studies report generally high concordance (approximately 80%–90%+) for tissue-of-origin classifiers, but reference standards are imperfect. Two randomized controlled trials comparing management guided by gene expression profiling versus usual care did not demonstrate a survival benefit. Therefore, evidence is insufficient to conclude that testing improves net health outcomes.

One commercially available assay (Tissue of Origin) has FDA 510(k) clearance; limited availability of site-specific treatments in trials restricted ability to detect benefit.

The PathWork® Tissue of Origin Test has explicit FDA 510(k) clearance limitations. The test is not intended to establish the origin of tumors that cannot be diagnosed according to current clinical and pathologic practice (for example, cancers of unknown primary). It is also not intended to subclassify tumors that can be diagnosed by current practice, nor to predict disease course, survival, or treatment efficacy, or to distinguish primary from metastatic tumors. Additionally, tumor types absent from the test database may have similar RNA expression patterns to database entries, which can produce indeterminate results or misclassification. Laboratory-developed alternatives (for example, CancerTYPE ID) are available under CLIA and are not FDA-reviewed in the same manner.

The clearance limitations reinforce that the assay’s intended use excludes establishing origin for tumors that remain unclassifiable by standard clinical and pathologic evaluation, and that results should be interpreted in the context of conventional diagnostic methods and CLIA laboratory practices.

Clinical evidence includes studies of test validity showing generally high concordance (about 80%–90%+) with imperfect reference standards, and two randomized controlled trials (one published, one reported in conference proceedings) that assessed clinical utility. Neither trial demonstrated a survival benefit when management was guided by gene expression profiling compared with usual care. Trial interpretation is limited because few site-specific treatments were available, so actual treatments often did not differ between arms. Consequently, the trials did not provide convincing evidence that using gene expression profiling to direct therapy improves patient-important outcomes, and the overall body of evidence is insufficient to support clinical utility.

There is insufficient evidence that tissue-of-origin gene expression assays improve net health outcomes or meaningfully change clinical decision-making for cancers of unknown primary. While clinical validity studies report high concordance with reference diagnoses, the reference standards are imperfect, and the two randomized trials identified did not show a survival benefit when treatment was guided by molecular tissue-of-origin results. Given these findings, current evidence does not demonstrate that testing alters management in a way that improves overall or disease-specific survival, quality of life, or other patient-centered outcomes.

Covered indications — none specified; evidence insufficient

Covered indications: No covered indications specified. Gene expression–based assays to determine tissue of origin in cancers of unknown primary are considered investigational due to insufficient evidence of clinical utility.

No circumstances in which testing is considered medically necessary are identified.

Procedure Codes and Coding Guidance

Investigational / Not Covered Procedure CodesCPTNot Covered

81479	Unlisted molecular pathology procedure (when used to report gene expression testing for CUP)
81504	Oncotype DX Colon or other gene expression assay (when used to report gene expression testing for CUP)
81540	Panel for gene expression (when used to report gene expression testing for CUP)
81599	Unlisted multianalyte assay with algorithmic analysis (when used to report gene expression testing for CUP)

Note: Use of these codes for CUP may result in denial based on investigative status and lack of demonstrated clinical utility for this indication. Always confirm member benefits and obtain required prior authorization when applicable.

Denial Risk

Investigational — Denial Risk

Investigational codes used to report gene expression testing for Cancer of Unknown Primary (CUP) may be denied. Confirm prior authorization and ensure medical-necessity documentation is submitted; if testing is billed with any of the listed codes for CUP, expect potential denial.

Affected codes: 81479, 81504, 81540, 81599
Action: Verify member benefit and obtain program-specific prior authorization where required before ordering/testing
Risk: Submissions for CUP with these codes are at high risk for denial as investigational

Provider Responsibilities and Operational Notes

Prior Authorization

Verify program-specific prior authorization requirements

Prior authorization and applicability of this policy vary by Capital Blue Cross program and product; some programs may have different prior authorization requirements (see program-specific guidance such as FEP PPO).

Policy applies only to certain Capital Blue Cross programs and products
FEP PPO: refer to FEP Medical Policy Manual for program-specific rules

Billing Rule

Code listing does not equal coverage — verify member benefits

Identification of a CPT code in the coding section does not guarantee coverage. Coverage determinations are made based on the member’s benefit program and eligibility; investigational codes listed for CUP testing are not necessarily covered.

Not Covered Uses

Use of gene expression assays or comprehensive genomic profiling to determine the site of origin of a tumor, to distinguish a primary tumor from a metastatic tumor, or to guide treatment selection in cancers of unknown primary is considered investigational and is not covered. The policy states there is insufficient evidence to conclude that these approaches improve health outcomes, and claims for such testing may be denied on that basis.

The policy lists specific CPT procedure codes that are investigational when used to report gene expression testing for cancer of unknown primary: 81479, 81504, 81540, and 81599. Use of these codes for this purpose is considered investigational and may be denied; the presence of a code here does not by itself determine coverage, which is governed by the member’s benefit plan.

Background and Clinical Context

Cancers of unknown primary (CUP) are metastatic tumors in which the site of origin cannot be identified after standard diagnostic evaluation. CUPs represent approximately 3% of all cancers. The majority are adenocarcinomas—about 70%—with the remainder including poorly differentiated carcinomas, squamous cell carcinomas, and rare neuroendocrine tumors. Prognosis is often poor for many patients with CUP; standard diagnostic workup typically includes imaging, laboratory studies, and immunohistochemistry to attempt to narrow the differential.

Definitions and Nomenclature

Genetics nomenclature and ACMG-AMP variant classification terms and HGVS nomenclature

Nomenclature standardHGVS nomenclature is used to report variants and is the international standard recommended by HGVS, the Human Variome Project, and HUGO

Variant classification frameworkACMG-AMP standards and guidelines provide the recommended terminology for sequence variant interpretation used in clinical laboratories

ACMG-AMP termsFive standard terms: pathogenic; likely pathogenic; variant of uncertain significance; likely benign; benign

Definitions

Definitions section statusNA

SourceSee policy definitions section

Eligibility Requirements

There are no covered eligibility criteria specified for gene expression or tissue-of-origin testing in cancers of unknown primary; the policy contains zero top-level covered eligibility nodes. In other words, the policy does not identify any circumstances under which these tests are considered medically necessary and covered.

Policy Revision History

2025-08-13Administrative UpdateLatest

Removed Benefit Variations section and updated Disclaimer.

2025-07-11Consensus Review

Comprehensive genomic profiling added to investigational policy statement; intent unchanged and coding reviewed.

2024-12-27Administrative Update

OpenPayer

Gene expression based assays for cancers of unknown primary